Amedisys (AMED) PT Cut to $47 at Mizuho Following Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive
November 7, 2016 7:48 AM ESTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $47.00, calling the sell-off after the COO resigned 'excessively overdone'.
Analyst Sheryl Skolnick commented, "AMED's shares dove Friday in concert with another C-Suite change at the... More
Amedisys (AMED) Taps Kindred Healthcare's Gerard as COO
November 4, 2016 6:33 AM EDTAmedisys, Inc. (Nasdaq: AMED) announced that industry leader Christopher Gerard will join the Company as Chief Operating Officer (COO) on January 3, 2017. Daniel McCoy will remain in this role until January 3, 2017.
Gerard brings more than 20 years of home health and hospice experience to the Company. In his new role, Gerard will be responsible for the Amedisys home health, hospice and personal care operations.
Chris has built an impressive track record of strategic, operational and financial accomplishments over the past two decades, said Amedisys President and Chief Executive Officer Paul... More
Amedisys (AMED) Misses Q3 EPS by 8c
November 3, 2016 5:03 PM EDTAmedisys (NASDAQ: AMED) reported Q3 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $361.6 million versus the consensus estimate of $361.08 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
... More